|Bid||109.80 x 100|
|Ask||150.00 x 100|
|Day's range||110.66 - 116.26|
|52-week range||15.17 - 116.67|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||100.29|
NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Martin Marietta Materials, Inc. (NYSE:MLM), AnaptysBio, Inc. (NASDAQ:ANAB), Hope Bancorp, Inc. (NASDAQ:HOPE), Agilysys, Inc. (NASDAQ:AGYS), Albany International Corporation (NYSE:AIN), and Goldman Sachs BDC, Inc. (NYSE:GSBD), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the J.P. Morgan 36th Annual Healthcare Conference on Tuesday, Jan. 9, 2018 at 12:00 p.m. PT at the Westin St. Francis in San Francisco.
The year 2017 marked a bounce back for the U.S. IPO market thanks to improving economy and consumer sentiment. Successful IPOs poured in primarily from the biotech and tech sectors.
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.